Current Hypertension Reviews最新文献_第7页

COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. COVID-19，血管紧张素转换酶2和肾素-血管紧张素系统抑制:实践意义。

IF 2.3

Current Hypertension Reviews Pub Date : 2022-01-01 DOI: 10.2174/1573402117666210121100201

Vasiliki Katsi, George Pavlidis, George Charalambous, Dimitrios Tousoulis, Konstantinos Toutouzas

{"title":"COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice.","authors":"Vasiliki Katsi, George Pavlidis, George Charalambous, Dimitrios Tousoulis, Konstantinos Toutouzas","doi":"10.2174/1573402117666210121100201","DOIUrl":"https://doi.org/10.2174/1573402117666210121100201","url":null,"abstract":"Background: Recent studies suggested that patients with coronavirus disease 2019 (COVID-19) who use renin-angiotensin system (RAS) inhibitors have an increased risk of respiratory failure and death. The hypothesis was that angiotensin-converting enzyme inhibitor (ACEIs) or angiotensin receptor blocker (ARBs) might up-regulate ACE2 expression that is used as a receptor for viral entry into cells.Objective: The purpose of this review is to discuss the existing evidence on the interaction between COVID-19 infection, ACE2 and ACEIs or ARBs and to examine the main implications for clinical practice. In addition, novel therapeutic strategies for blocking ACE2-mediated COVID-19 infection will be displayed.Methods: We performed a comprehensive review of the literature to identify data from clinical and experimental studies for the association between COVID-19 infection, ACE2 and RAS inhibition.Results: The current clinical and experimental evidence for ACEIs or ARBs to facilitate severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) is insufficient to suggest discontinuing these drugs. Several observational studies arrive at the conclusion that the continued use of RAS inhibitors is unlikely to be harmful in COVID-19-positive patients.Conclusions: Further randomized trials are needed to answer the question of whether RAS inhibitors are harmful or beneficial to patients with COVID-19.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"18 1","pages":"3-10"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38842826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle. 未控制的高血压对左心室纵向收缩功能的影响。

IF 2.3

Current Hypertension Reviews Pub Date : 2022-01-01 DOI: 10.2174/1573402117666210218105338

Nabila Soufi Taleb Bendiab, Salim Benkhedda, Latifa Henaoui, Abderrahim Meziane Tani

{"title":"The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle.","authors":"Nabila Soufi Taleb Bendiab, Salim Benkhedda, Latifa Henaoui, Abderrahim Meziane Tani","doi":"10.2174/1573402117666210218105338","DOIUrl":"https://doi.org/10.2174/1573402117666210218105338","url":null,"abstract":"Background: The assessment of the longitudinal component of left ventricular (LV) function is of major clinical importance for the early detection of LV contractile impairment. The aim of this study was to determine the impact of uncontrolled hypertension, on LV longitudinal systolic performance.Methods: The study population included 400 hypertensive patients: 271 patients with uncontrolled blood pressure (BP) and 112 without controlled BP, all patients underwent a complete ultrasound evaluation with the calculation of the LV mass, evaluation of diastolic function as well as longitudinal systolic function.Results: Conventional echo demonstrated that uncontrolled patients had increased LV mass (P 0.007), LA (left auricular) dimension (P 0.004), left ventricular wall thickness and impairment of diastolic function (E/E'6 ± 2.1 vs 7.4 ±3.0 P=0.001) while no affection of systolic function could be detected. By deformation imaging, there was a reduction in longitudinal strain (apical 4 view -16.2 ±2.9 vs -18.2± 2.6 P 0.02, apical 3 view -17.3 ± 3.3 vs. -18.9 ± 4.1 P 0.01). Similarly, systolic strain rate (SRsys) and early diastolic SR (SRe) reduced significantly in longitudinal direction.Conclusion: Although EF was not different between uncontrolled patients and controls, LV longitudinal strain and strain rate by 2D speckle tracking were lower in the uncontrolled group.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"18 1","pages":"70-77"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Association of Newly Diagnosed Hypertension and Polypharmacy with Frailty in a Tertiary Hospital Patients from Maracaibo City, Venezuela. 委内瑞拉马拉开波市某三级医院患者新诊断的高血压和多种药物与虚弱的关系

IF 2.3

Current Hypertension Reviews Pub Date : 2022-01-01 DOI: 10.2174/1573402117666211005122757

Juan Salazar, Isabel Borges, Alejandra Rivas-Motenegro, Nelson Villasmil-Hernandez, Manuel Nava, Roberto Añez

{"title":"Association of Newly Diagnosed Hypertension and Polypharmacy with Frailty in a Tertiary Hospital Patients from Maracaibo City, Venezuela.","authors":"Juan Salazar, Isabel Borges, Alejandra Rivas-Motenegro, Nelson Villasmil-Hernandez, Manuel Nava, Roberto Añez","doi":"10.2174/1573402117666211005122757","DOIUrl":"https://doi.org/10.2174/1573402117666211005122757","url":null,"abstract":"Background: As a syndrome of physiological vulnerability and multifactorial progressive decline tightly related to age, frailty has been associated with several illnesses, and in particular cardiovascular disease.Objective: To assess the factors associated with the frailty syndrome in older adults evaluated in the outpatient clinic of a tertiary hospital from Maracaibo city, Venezuela.Materials and methods: An observational, analytical, cross-sectional study was performed on subjects of both genders, over 60 years old that went to the Internal Medicine outpatient clinic of the Hospital General del Sur \"Dr. Pedro Iturbe\" from Maracaibo city, Venezuela. Sampling was performed via a non-probabilistic, intentional method. For each subject with frailty or pre-frailty, a control subject was selected in a 1:1 ratio according to gender; several risk factors were interrogated. The state of frailty was determined through the FRAIL scale.Results: Of the 201 assessed patients, 49.3% (n=99) were non-frail, 19.9% (n=40) were pre-frail and 30.8% (n=62) were frail. The population's overall age was 68.8±6.8 in non-frails, 69.1±7.7 in pre-frails, and 68.6±7.1 in frails. In the multivariate analysis, subjects with frailty and pre-frailty were most likely to be receiving polypharmacy (OR: 2.36, CI95%: 1.05-5.37; P=0.04) and have hypertension during the study (OR: 10.19, CI95%: 3.86-26.89; P<0.01).Conclusion: The newly diagnosed hypertension and presence of polypharmacy were the factors most associated with frailty and pre-frailty in older adults evaluated in a tertiary hospital from Maracaibo city, Venezuela.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"18 1","pages":"85-90"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39509844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unravelling the Mechanistic Role of ACE2 and TMPRSS2 in Hypertension: A Risk Factor for COVID-19. 揭示ACE2和TMPRSS2在高血压中的机制作用:COVID-19的危险因素

IF 2.3

Current Hypertension Reviews Pub Date : 2022-01-01 DOI: 10.2174/1573402118666220816090809

Nalini Govender, Olive Khaliq, Jagidesa Moodley, Thajasvarie Naicker

{"title":"Unravelling the Mechanistic Role of ACE2 and TMPRSS2 in Hypertension: A Risk Factor for COVID-19.","authors":"Nalini Govender, Olive Khaliq, Jagidesa Moodley, Thajasvarie Naicker","doi":"10.2174/1573402118666220816090809","DOIUrl":"https://doi.org/10.2174/1573402118666220816090809","url":null,"abstract":"Background: This review explores the mechanistic action of angiotensin-converting enzyme- 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) in the renin-angiotensinaldosterone system (RAAS) that predisposes hypertensive patients to the adverse outcome of severe COVID-19.Methods and results: Entry of SARS-CoV-2 into the host cell via ACE2 disrupts the RAAS system, creating an imbalance between ACE and ACE2, with an increased inflammatory response, leading to hypertension (HTN), pulmonary vasoconstriction and acute respiratory distress. SARSCoV- 2 may also predispose infected individuals with existing HTN to a greater risk of severe COVID-19 complications. In the duality of COVID-19 and HTN, the imbalance of ACE and ACE2 results in an elevation of AngII and a decrease in Ang (1-7), a hyperinflammatory response and endothelial dysfunction. Endothelial dysfunction is the main factor predisposing hypertensive patients to severe COVID-19 and vice-versa.Conclusion: Despite the increase in ACE2 expression in hypertensive SARS-CoV-2 infected patients, ARBs/ACE inhibitors do not influence their severity and clinical outcomes, implicating continued usage. Future large-scale clinical trials are warranted to further elucidate the association between HTN and SARS-CoV-2 infection and the use of ARBs/ACEIs in SARS-CoV-2 hypertensive patients.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"18 2","pages":"130-137"},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10617390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The Role of (Pro)Renin Receptor in the Metabolic Syndrome. 肾素受体在代谢综合征中的作用。

IF 2.3

Current Hypertension Reviews Pub Date : 2022-01-01 DOI: 10.2174/1573402118666220216104816

Kellea Nichols, Frederique Yiannikouris

引用次数: 1

Whole Milk and Full-Fat Dairy Products and Hypertensive Risks. 全脂牛奶和全脂乳制品与高血压风险

IF 2.3

Current Hypertension Reviews Pub Date : 2021-12-17 DOI: 10.2174/1573402116666200804152649

Stephen J Roy, Hirofumi Tanaka

{"title":"Whole Milk and Full-Fat Dairy Products and Hypertensive Risks.","authors":"Stephen J Roy, Hirofumi Tanaka","doi":"10.2174/1573402116666200804152649","DOIUrl":"https://doi.org/10.2174/1573402116666200804152649","url":null,"abstract":"Lifestyle modifications in the form of diet and exercise are generally the first-line approach to reduce hypertensive risk and overall cardiovascular disease (CVD) risk. Accumulating research evidence has revealed that consumption of non- and low-fat dairy products incorporated into the routine diet is an effective means to reduce elevated blood pressure and improve vascular functions. However, the idea of incorporating whole-fat or full-fat dairy products in the normal routine diet as a strategy to reduce CVD risk has been met with controversy. The aim of this review was to evaluate both sides of the argument surrounding saturated fat intake and CVD risk from the standpoint of dairy intake. Throughout the review, we examined observational studies on relationships between CVD risk and dairy consumption, dietary intervention studies using non-fat and whole-fat dairy, and mechanistic studies investigating physiological mechanisms of saturated fat intake that may help to explain increases in cardiovascular disease risk. Currently available data have demonstrated that whole-fat dairy is unlikely to augment hypertensive risk when added to the normal routine diet but may negatively impact CVD risk. In conclusion, whole-fat dairy may not be a recommended alternative to non- or low-fat dairy products as a mean to reduce hypertensive or overall CVD risk.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"17 3","pages":"181-195"},"PeriodicalIF":2.3,"publicationDate":"2021-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38227385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meet the Section Editor 会见剖面编辑器

IF 2.3

Current Hypertension Reviews Pub Date : 2021-08-01 DOI: 10.2174/157340211702211025095357

Hao-min Cheng

引用次数: 0

Meet Our Editorial Board Member 会见我们的编辑委员会成员

IF 2.3

Current Hypertension Reviews Pub Date : 2021-06-09 DOI: 10.2174/157340211701210527092713

G. Tse

{"title":"Meet Our Editorial Board Member","authors":"G. Tse","doi":"10.2174/157340211701210527092713","DOIUrl":"https://doi.org/10.2174/157340211701210527092713","url":null,"abstract":"Gary received his Ph.D. in physical/organic chemistry from Indiana University in 1982 under the direction of Dr. John E. Bartmess using Ion Cyclotron Resonance Spectrometry to study gas-phase ion chemistry. Following his Ph.D., he performed postdoctoral research with Dr. Paul Kebarle at the University of Alberta in Canada using High-Pressure Mass Spectrometry to study gas-phase ion chemistry. Gary joined Janssen Pharmaceutical Research and Development a subsidiary of Johnson & Johnson in 1985. During his 32-year career with Janssen Pharmaceutical R & D, Gary has managed a variety of functions within the drug discovery units. These functions include the NMR, GC/MS & LC/MS/MS spectroscopy group, the medicinal chemistry intermediates group, the large-scale separation group, the drug discovery in-vivo/in-vitro PK/ADME groups and the compound management group. His research interests primarily involve the use of advanced spectrometric and chromatographic techniques to chemically and biologically characterize new drug targets and drug entities. Presently, he is working on establishing targeted and untargeted metabolomic methods to understand “on” and “off” target effects to improve drug efficacy and reduce drug toxicity. He is the author of over 150 publications, two patents, over 50 poster presentations, and has given over 40 invited talks at universities, companies, and conferences. He is the co-editor of Frontier in Drug Design & Discovery (volumes 1-4), editor of Optimization in Drug Discovery: In-Vitro Methods (volumes 1-2).","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":"1 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42172561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fungal infection in cystic fibrosis. 囊性纤维化中的真菌感染。

IF 2.3

Current Hypertension Reviews Pub Date : 2021-05-01 DOI: 10.2174/1573402117666210511012609

A. Sarvestani, M. Almasian, Amirhossein Nafari

{"title":"Fungal infection in cystic fibrosis.","authors":"A. Sarvestani, M. Almasian, Amirhossein Nafari","doi":"10.2174/1573402117666210511012609","DOIUrl":"https://doi.org/10.2174/1573402117666210511012609","url":null,"abstract":"BACKGROUND\u0000The prevalence of fungal infections has been increasing in recent years. Cystic fibrosis (CF) is a genetic disorder that affects organs such as the intestines, liver, pancreas, and especially the lungs.\u0000\u0000\u0000INTRODUCTION\u0000Fungal pathogens are becoming a challenge in CF. Advanced medical science is associated with longer life expectancy in some patient groups.\u0000\u0000\u0000METHOD\u0000A review was conducted on studies found on such online databases as Google Scholar, PubMed, and Scopus. Internet-based searches were performed on these databases for cystic fibrosis, respiratory infections, and fungal infection profiling to identify all relevant studies published between 2010 and 2020.\u0000\u0000\u0000RESULT\u0000Fungal pathogens most frequently isolated from the respiratory tract include the Aspergillus genus, the Candida genus, Scedosporium apiospermum, and the Rasamsonia genus. In cystic fibrosis, these organisms usually colonize the respiratory and intestinal tracts and cause hypersensitivity responses and invasive diseases.\u0000\u0000\u0000CONCLUSION\u0000Fungus-patient interactions are complicated and depend on various factors. Moreover, the emergence of drug-resistant species is a serious health issue, and the development of new treatments is crucial.","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49497176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meet Our Editorial Board Member 见见我们的编辑委员会成员

IF 2.3

Current Hypertension Reviews Pub Date : 2021-01-14 DOI: 10.2174/157340211603201127093819

A. Bagrov

引用次数: 0